Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes Journal Article
| Authors: | Zener, R.; Yoon, H.; Ziv, E.; Covey, A.; Brown, K. T.; Sofocleous, C. T.; Thornton, R. H.; Boas, F. E. |
| Article Title: | Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes |
| Abstract: | Purpose: To evaluate initial response and overall survival of neuroendocrine tumor (NET) liver metastases initially treated with transarterial embolization (TAE) using spherical particles of different sizes. Methods: A single-institution retrospective review was performed of 160 patients with NET liver metastases initially treated with TAE using < 100 μm (n = 77) or only ≥ 100 μm (n = 83) spherical particles. For each patient, we evaluated: initial response by mRECIST, time to progression, overall survival, complications, primary site, tumor grade and degree of differentiation, volume of liver disease, extrahepatic disease, NET-related symptoms, comorbidities, Child–Pugh score, performance status, lobar versus selective embolization, and arteriovenous shunting. Results: Initial response was higher for TAE using particles < 100 versus TAE using only particles ≥ 100 μm (64 vs 42%, p = 0.007). Multivariate logistic regression showed that use of particles < 100 μm and liver < 50% replaced with tumor were independent predictors of a better initial response rate. There was no difference in major or minor complications between the two particle size groups. Median overall survival after TAE was 55 months for well- to moderately differentiated NET and 13 months for poorly differentiated or undifferentiated NET. There was no significant difference in survival between TAE patients treated with < 100 versus only ≥ 100-μm particles. Conclusion: NET patients treated with TAE using particles < 100 μm had better initial response, but the same overall survival, compared to TAE using only particles ≥ 100 μm. © 2019, Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). |
| Keywords: | adult; controlled study; major clinical study; overall survival; review; hypertension; cancer patient; outcome assessment; cancer grading; progression free survival; tumor differentiation; retrospective study; dyspnea; neuroendocrine tumor; postoperative complication; liver metastasis; thorax pain; comorbidity; mental disease; carcinoid; bacteremia; liver abscess; atrial fibrillation; particle size; aspiration pneumonia; lung edema; acute cholecystitis; arteriovenous shunt; celiac artery stenosis; child pugh score; human; male; female; priority journal; transarterial embolization; artificial embolization; contrast induced nephropathy; post embolization syndrome |
| Journal Title: | CardioVascular and Interventional Radiology |
| Volume: | 42 |
| Issue: | 4 |
| ISSN: | 0174-1551 |
| Publisher: | Springer |
| Date Published: | 2019-04-01 |
| Start Page: | 569 |
| End Page: | 576 |
| Language: | English |
| DOI: | 10.1007/s00270-018-02160-y |
| PUBMED: | 30627774 |
| PROVIDER: | scopus |
| PMCID: | PMC6395494 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work